BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 15788594)

  • 1. Value of FDG PET in the assessment of patients with multiple myeloma.
    Bredella MA; Steinbach L; Caputo G; Segall G; Hawkins R
    AJR Am J Roentgenol; 2005 Apr; 184(4):1199-204. PubMed ID: 15788594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic utility of FDG PET in multiple myeloma.
    Jadvar H; Conti PS
    Skeletal Radiol; 2002 Dec; 31(12):690-4. PubMed ID: 12483429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma.
    Hur J; Yoon CS; Ryu YH; Yun MJ; Suh JS
    Acta Radiol; 2008 May; 49(4):427-35. PubMed ID: 18415787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial results in the assessment of multiple myeloma using 18F-FDG PET.
    Schirrmeister H; Bommer M; Buck AK; Müller S; Messer P; Bunjes D; Döhner H; Bergmann L; Reske SN
    Eur J Nucl Med Mol Imaging; 2002 Mar; 29(3):361-6. PubMed ID: 12002711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
    Ak I; Gulbas Z
    Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma.
    Breyer RJ; Mulligan ME; Smith SE; Line BR; Badros AZ
    Skeletal Radiol; 2006 Sep; 35(9):632-40. PubMed ID: 16758246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
    Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
    Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.
    Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosini V; Montini GC; Al-Nahhas A; Franchi R; Fanti S
    World J Surg Oncol; 2007 Jun; 5():68. PubMed ID: 17584499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
    Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
    J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone.
    Nanni C; Rubello D; Zamagni E; Castellucci P; Ambrosini V; Montini G; Cavo M; Lodi F; Pettinato C; Grassetto G; Franchi R; Gross MD; Fanti S
    In Vivo; 2008; 22(4):513-7. PubMed ID: 18712181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The value of fluorodeoxyglucose positron emission tomography in multiple myeloma].
    Adam Z; Bolcák K; Stanícek J; Pour L; Hájek R; Krejcí M; Prásek J; Neubauer J; Mareschova Y; Vorlícek J
    Vnitr Lek; 2006 Mar; 52(3):207-14. PubMed ID: 16722151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
    Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
    Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body (18)F-FDG PET identifies high-risk myeloma.
    Durie BG; Waxman AD; D'Agnolo A; Williams CM
    J Nucl Med; 2002 Nov; 43(11):1457-63. PubMed ID: 12411548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results.
    Nanni C; Zamagni E; Farsad M; Castellucci P; Tosi P; Cangini D; Salizzoni E; Canini R; Cavo M; Fanti S
    Eur J Nucl Med Mol Imaging; 2006 May; 33(5):525-31. PubMed ID: 16453155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).
    Nanni C; Zamagni E; Versari A; Chauvie S; Bianchi A; Rensi M; Bellò M; Rambaldi I; Gallamini A; Patriarca F; Gay F; Gamberi B; Cavo M; Fanti S
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):414-21. PubMed ID: 26475305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma.
    Mileshkin L; Blum R; Seymour JF; Patrikeos A; Hicks RJ; Prince HM
    Eur J Haematol; 2004 Jan; 72(1):32-7. PubMed ID: 14962260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma.
    Sager S; Ergül N; Ciftci H; Cetin G; Güner SI; Cermik TF
    Skeletal Radiol; 2011 Jul; 40(7):843-7. PubMed ID: 21229354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
    Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M
    Haematologica; 2007 Jan; 92(1):50-5. PubMed ID: 17229635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT.
    Ak İ; Onner H; Akay OM
    Ann Hematol; 2015 Sep; 94(9):1567-75. PubMed ID: 26068066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-Body MRI versus PET in assessment of multiple myeloma disease activity.
    Shortt CP; Gleeson TG; Breen KA; McHugh J; O'Connell MJ; O'Gorman PJ; Eustace SJ
    AJR Am J Roentgenol; 2009 Apr; 192(4):980-6. PubMed ID: 19304704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.